Subsequently, June et al. generated a CAR targeting a tumor-specific glycoform (MUC1-Tn), which selectively targeted a range of MUC1+ tumors (leukemia, pancreatic cancer and breast cancer) leaving normal cells including cardiomyocytes, osteoblasts, renal epithelial cells and pulmonary artery endothelial cells untouched [46]. Here, MUC1 is linked to leukemia.